STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
HORSHAM, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
Coronavirus
TechImmune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- TechImmune, LLC., a biotechnology company developing a broad-spectrum, next generation coronavirus...
Todos Medical Announces Insolvency Proceedings in Israel
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, Israel, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd....
Pharma-Bio Serv Announces Special Dividend
DORADO, PUERTO RICO / ACCESSWIRE / December 21, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a...
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE)...
National Minority Quality Forum Announces Published Results of Baseline Minority and Rural Coronavirus Insights Study in Population Health Management
Study finds that despite past headlines, COVID-19 infection rates are higher amongst people of color.Washington, D.C.--(Newsfile Corp. - December 20,...
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on...
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation...
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James...
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new...
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleLONDON, Ontario and...
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major...
UpHealth Enters into Definitive Agreement for Sale of Cloudbreak Health Business to GTCR for $180 Million
Proceeds Will be Utilized to Pay Down All Unsecured Debt and Approximately 45% of Secured Debt UpHealth Will Focus on...
NanoViricides Has Filed its Quarterly Report – NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed...
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to ProgressPlanning for APVO436 Phase 2...
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of...
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...